# OnCo record nct07502300 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07502300/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07502300", "NCT07502300" ;
  schema:name "A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa"@en ;
  schema:description "A phase 3 trial of Izalontamab brengitecan, Tislelizumab, Carboplatin in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07502300/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07502300> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-06-15" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .